Hematopathology — MCQs

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 981: Examination of a peripheral blood smear demonstrates a leukemia composed of small mature lymphocytes without blast forms. Which of the following is the most likely age of this patient?

A. 1 year
B. 45 years
C. 5 years
D. 65 years (Correct Answer)

Explanation: **Explanation:** The peripheral blood smear description—**small mature lymphocytes without blast forms**—is the classic morphological hallmark of **Chronic Lymphocytic Leukemia (CLL)** [1]. In CLL, the neoplastic cells are small, round, mature-appearing B-lymphocytes with clumped "soccer-ball" chromatin and scant cytoplasm. Characteristically, these fragile cells often rupture during smear preparation, creating **Smudge cells (Basket cells)** [1]. **1. Why 65 years is correct:** CLL is the most common leukemia in the Western world and is a disease of the **elderly** [2]. The median age at diagnosis is approximately **65–70 years**. It is extremely rare in children and young adults. **2. Why other options are incorrect:** * **1 year and 5 years (Options A & C):** These age groups are typical for **Acute Lymphoblastic Leukemia (ALL)**. Morphologically, ALL would show **lymphoblasts** (large cells with high N:C ratio, fine chromatin, and nucleoli), not mature lymphocytes [3]. Factors such as age younger than 2 years are associated with a worse prognosis in ALL [3]. * **45 years (Option B):** While some chronic leukemias like CML can occur in middle age, CLL specifically targets the geriatric population [2]. A 45-year-old is more likely to present with CML, which has a peak incidence in the fifth to sixth decades of life, or AML rather than the mature lymphocytic profile of CLL [4]. **Clinical Pearls for NEET-PG:** * **Immunophenotype:** CLL cells are characteristically **CD5+, CD19+, CD20+ (weak), and CD23+** [1]. The co-expression of CD5 (a T-cell marker) on B-cells is pathognomonic. * **Richter Transformation:** In ~5% of cases, CLL can transform into a high-grade **Diffuse Large B-cell Lymphoma (DLBCL)**, signaled by sudden lymph node enlargement and systemic symptoms. * **Staging:** Uses the **Rai** or **Binet** systems, primarily based on lymphocytosis, lymphadenopathy, organomegaly, and cytopenias (anemia/thrombocytopenia). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 602. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 612-613. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 600-602. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 625-626.

Question 982: Golf ball inclusion bodies in RBCs are seen in which condition?

A. Normal reticulocytes
B. HbH disease (Correct Answer)
C. Pernicious anaemia
D. G6PD deficiency

Explanation: **Explanation:** **HbH Disease (Correct Answer):** HbH disease is a form of **α-thalassemia** characterized by the deletion of three out of four alpha-globin genes (--/-α) [1], [2]. This results in an excess of beta (β) chains, which tetramerize to form **Hemoglobin H (β4)**. HbH is unstable and precipitates within the red blood cells as they age. When stained with **supravital stains** (like Brilliant Cresyl Blue or New Methylene Blue), these precipitates appear as multiple, small, uniform, greenish-blue dots distributed throughout the RBC, giving it a characteristic **"golf ball"** or "raspberry" appearance [1]. **Analysis of Incorrect Options:** * **Normal reticulocytes:** While they also require supravital staining, they show a **linear network or clumps** of ribosomal RNA (reticulum), not the uniform "golf ball" dots. * **Pernicious anaemia:** This is a megaloblastic anemia characterized by Howell-Jolly bodies (nuclear remnants) and basophilic stippling, but not HbH inclusions. * **G6PD deficiency:** Oxidative stress leads to the precipitation of denatured hemoglobin called **Heinz bodies** [3]. While they also require supravital stains, they are typically larger, fewer in number, and often attached to the RBC membrane (later removed by splenic macrophages to form "bite cells") [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Stain used:** Supravital stain (Brilliant Cresyl Blue) is essential; these inclusions are not visible on routine Leishman or Giemsa stains [1]. * **HbH Electrophoresis:** Shows a fast-moving band (anodal) [1]. * **Hb Barts:** A tetramer of gamma chains (γ4) seen in Hydrops Fetalis (4-gene deletion) [2]. * **Differential:** Do not confuse "golf ball" appearance (HbH) with "pitted" appearance (siderocytes) or "Maltese cross" (Babesiosis). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 600-601. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 649-650. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 642-643.

Question 983: D-Dimer values may be increased in all of the following conditions except?

A. Myocardial infarction
B. Pneumonia
C. Anticoagulant therapy (Correct Answer)
D. Pregnancy

Explanation: **Explanation:** **D-Dimer** is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It specifically indicates that both **thrombin generation** (clot formation) and **plasmin activation** (clot breakdown) have occurred [5]. **Why Anticoagulant Therapy is the Correct Answer:** Anticoagulants (like Heparin or Warfarin) inhibit the formation of new clots and prevent the extension of existing ones [2]. By reducing thrombin activity and subsequent fibrin formation, there is less fibrin available for plasmin to degrade. Consequently, **anticoagulant therapy leads to a decrease in D-Dimer levels.** It is often used as a marker to monitor the effectiveness of treatment in conditions like DVT. **Analysis of Incorrect Options:** * **Myocardial Infarction (MI):** Acute coronary syndromes involve plaque rupture and subsequent thrombus formation. The body’s endogenous fibrinolytic system attempts to break this down, leading to **elevated** D-Dimer levels. * **Pneumonia:** Any severe systemic inflammation or infection triggers the coagulation cascade (via cytokines). This state of "inflammation-induced coagulation" results in **increased** D-Dimer [3]. * **Pregnancy:** Pregnancy is a physiological hypercoagulable state. Fibrinogen levels and thrombin generation increase progressively, leading to **elevated** baseline D-Dimer levels, especially in the third trimester [1]. **High-Yield Clinical Pearls for NEET-PG:** * **High Negative Predictive Value:** The primary clinical use of D-Dimer is to **rule out** DVT or Pulmonary Embolism in patients with low pre-test probability (Wells Score). * **Specificity:** D-Dimer is highly sensitive but **low in specificity**. It can be raised in trauma, surgery, malignancy, liver disease, and old age. * **DIC:** D-Dimer is a key diagnostic marker for Disseminated Intravascular Coagulation, reflecting widespread fibrin split products [4]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 624-625. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 583-584. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 671-672. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 625-626. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 130.

Question 984: What is the common name for coagulation factor VII?

A. Thromboplastin
B. Accelerin
C. Proconvertin (Correct Answer)
D. Antihemophilic factor

Explanation: **Explanation:** Coagulation Factor VII is a vitamin K-dependent serine protease synthesized in the liver [1]. It plays a pivotal role in the **extrinsic pathway** of the coagulation cascade. **1. Why Proconvertin is correct:** Factor VII is commonly known as **Proconvertin** (or Serum Prothrombin Conversion Accelerator - SPCA). It is activated by Tissue Factor (Factor III) to form Factor VIIa. This complex then activates Factor X into Xa, serving as the primary initiator of the coagulation process in vivo. **2. Analysis of Incorrect Options:** * **Option A: Thromboplastin:** This is the common name for **Factor III** (Tissue Factor). It is released from damaged vascular endothelial cells to initiate the extrinsic pathway. * **Option B: Accelerin:** This refers to **Factor Va**. Factor V is known as Proaccelerin (labile factor); once activated by thrombin, it becomes Accelerin (Va), acting as a cofactor in the prothrombinase complex. * **Option C: Antihemophilic factor (AHF):** This is the common name for **Factor VIII**. A deficiency in this factor leads to Hemophilia A. **High-Yield Clinical Pearls for NEET-PG:** * **Shortest Half-life:** Factor VII has the shortest half-life (approx. 4–6 hours) among all coagulation factors. * **Warfarin Monitoring:** Because of its short half-life, Factor VII is the first factor to decrease when starting Warfarin therapy [1]. This is why the **Prothrombin Time (PT/INR)** is used to monitor extrinsic pathway activity and early Warfarin effect. * **Vitamin K Dependency:** Factors II, VII, IX, and X (and Proteins C and S) are all Vitamin K-dependent [1]. * **Factor VII Deficiency:** A rare autosomal recessive bleeding disorder that presents with a prolonged PT but a normal aPTT. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 582-583.

Question 985: Which of the following findings is NOT compatible with a diagnosis of chronic myelomonocytic leukemia?

A. Absence of Philadelphia chromosome
B. More than 20% blasts in blood or bone marrow (Correct Answer)
C. Both absence of Philadelphia chromosome and more than 20% blasts in blood or bone marrow
D. None of the above

Explanation: **Explanation:** Chronic Myelomonocytic Leukemia (CMML) is a clonal hematopoietic malignancy classified by the WHO under **MDS/MPN overlap syndromes**. It is characterized by features of both myelodysplasia (ineffective hematopoiesis) and myeloproliferation (monocytosis). **1. Why Option B is the Correct Answer:** According to the WHO diagnostic criteria, the blast count (including myeloblasts, monoblasts, and promonocytes) in the peripheral blood and bone marrow must be **less than 20%** [1]. If the blast count reaches or exceeds 20%, the diagnosis changes to **Acute Myeloid Leukemia (AML)** [1]. Therefore, a finding of >20% blasts is fundamentally incompatible with a diagnosis of CMML. **2. Analysis of Incorrect Options:** * **Option A (Absence of Philadelphia chromosome):** This is a **required** diagnostic criterion for CMML. The presence of the *BCR-ABL1* fusion gene (Philadelphia chromosome) would instead point toward Chronic Myeloid Leukemia (CML) [2]. Since its absence is compatible with CMML, this option is incorrect as a "non-compatible" finding. * **Option C & D:** These are incorrect because Option B is the specific standalone criterion that excludes CMML. **High-Yield Clinical Pearls for NEET-PG:** * **Persistent Monocytosis:** The hallmark of CMML is a persistent peripheral blood monocytosis (**>0.5 x 10⁹/L** and **>10%** of the differential count). * **Subtypes:** CMML is divided into CMML-0 (<5% blasts), CMML-1 (5-9% blasts), and CMML-2 (10-19% blasts). * **Genetic Markers:** While no single mutation is pathognomonic, mutations in *TET2*, *SRSF2*, and *ASXL1* are frequently seen. * **Splenomegaly:** Often present due to the myeloproliferative component of the disease. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 613-614. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 624-625.

Question 986: A patient presents with anemia and peripheral blood smear findings suggestive of thalassemia. A positive family history is also noted. Which investigation is essential to establish the diagnosis?

A. Erythrocyte Sedimentation Rate (ESR) estimation
B. Blood spherocyte estimation
C. Bone marrow aspiration
D. Hemoglobin (Hb) electrophoresis (Correct Answer)

Explanation: **Explanation:** The clinical presentation of anemia, characteristic peripheral smear findings (such as microcytic hypochromic cells, target cells, and basophilic stippling), and a positive family history strongly suggest a hereditary hemoglobinopathy like **Thalassemia** [1]. **Why Hemoglobin (Hb) Electrophoresis is the Correct Answer:** Hb electrophoresis is the gold standard diagnostic tool for thalassemia [1]. It works by separating different hemoglobin fractions based on their electrical charge. * In **$\beta$-Thalassemia minor**, electrophoresis typically shows an elevated **HbA2 (>3.5%)** and sometimes elevated HbF [3]. * In **$\beta$-Thalassemia major**, there is a marked increase in **HbF** with little to no HbA [1]. This investigation is essential to confirm the diagnosis and differentiate thalassemia from other microcytic anemias like Iron Deficiency Anemia (IDA) [1][2]. **Why Other Options are Incorrect:** * **A. ESR estimation:** ESR is a non-specific marker of inflammation and has no diagnostic value in identifying hemoglobinopathies. * **B. Blood spherocyte estimation:** Spherocytes are characteristic of Hereditary Spherocytosis or Autoimmune Hemolytic Anemia, not thalassemia (where target cells are predominant). * **C. Bone marrow aspiration:** While it may show erythroid hyperplasia [4], it is invasive and non-specific. It cannot differentiate between various causes of microcytic anemia or confirm a genetic hemoglobin defect. **High-Yield Clinical Pearls for NEET-PG:** * **Mentzer Index:** (MCV/RBC count) < 13 suggests Thalassemia; > 13 suggests IDA. * **NESTROFT:** (Naked Eye Single Tube Red Cell Osmotic Fragility Test) is used as a cost-effective **screening** tool for Thalassemia trait in mass populations. * **HPLC (High-Performance Liquid Chromatography):** Often preferred over electrophoresis in modern labs for its higher sensitivity and quantification accuracy. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 600-601. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 590-591. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 649-650. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 648-649.

Question 987: Maturation defect of RBCs is seen in which of the following conditions?

A. Vitamin B12 deficiency (Correct Answer)
B. Vitamin B6 deficiency
C. Iron deficiency
D. Protein deficiency

Explanation: **Explanation:** The correct answer is **Vitamin B12 deficiency**. This condition leads to a **maturation defect** known as **Megaloblastic Anemia** [1]. **1. Why Vitamin B12 deficiency is correct:** Vitamin B12 (Cobalamin) and Folic acid are essential cofactors for DNA synthesis. Specifically, B12 is required for the conversion of homocysteine to methionine, which is linked to the production of thymidine [3]. When B12 is deficient, DNA synthesis is impaired, while RNA and protein synthesis (hemoglobin production) continue at a normal rate. This results in **nuclear-cytoplasmic asynchrony**: the nucleus remains immature (large and lacy) while the cytoplasm matures and expands [3]. This "maturation defect" leads to the formation of large, fragile macro-ovalocytes. **2. Why the other options are incorrect:** * **Iron deficiency (C):** This is a **hemoglobinization defect**, not a maturation defect. Lack of iron prevents adequate heme synthesis, resulting in small, pale cells (**Microcytic Hypochromic anemia**). * **Vitamin B6 deficiency (B):** Pyridoxine (B6) is a cofactor for ALA synthase, the rate-limiting enzyme in heme synthesis. Deficiency leads to **Sideroblastic anemia**, which is also a defect in heme synthesis rather than nuclear maturation. * **Protein deficiency (D):** This typically leads to a normocytic normochromic anemia due to a general decrease in erythropoiesis and metabolic rate (e.g., in Kwashiorkor). **High-Yield Clinical Pearls for NEET-PG:** * **Peripheral Smear:** Look for **Macro-ovalocytes** and **Hypersegmented neutrophils** (≥ 5 lobes in > 5% of neutrophils or a single neutrophil with ≥ 6 lobes) [2]. * **Bone Marrow:** Characterized by "Megaloblastic change" and **ineffective erythropoiesis** (intramedullary hemolysis), leading to increased LDH and indirect bilirubin [3]. * **Neurological Symptoms:** Only B12 deficiency (not Folate) causes **Subacute Combined Degeneration (SCD)** of the spinal cord due to the accumulation of methylmalonic acid (MMA) [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 130-131. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 654. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 654-655.

Question 988: Which of the following findings is seen in megaloblastic anemia?

A. Howell-Jolly bodies
B. Cabot rings
C. Basophilic stippling
D. All of the above (Correct Answer)

Explanation: **Explanation:** Megaloblastic anemia is characterized by **impaired DNA synthesis** with preserved RNA/protein synthesis, leading to **nuclear-cytoplasmic asynchrony** [2]. This results in ineffective erythropoiesis and the premature destruction of erythroblasts in the bone marrow. **Why "All of the above" is correct:** The peripheral smear in megaloblastic anemia reflects this dyserythropoiesis through several characteristic inclusions: 1. **Howell-Jolly Bodies:** These are small, round, purple-blue nuclear remnants (clusters of DNA) that persist in the RBC because the "pitting" mechanism of the spleen is overwhelmed or the erythropoiesis is severely disordered. 2. **Cabot Rings:** These are thin, red-violet, thread-like strands in the shape of a loop or figure-of-eight. They are believed to be remnants of the **mitotic spindle** or denatured proteins. 3. **Basophilic Stippling:** These are fine or coarse blue granules representing **precipitated ribosomes** and RNA. While also seen in lead poisoning, they are a common feature of the disordered erythropoiesis in megaloblastic anemia. **High-Yield Clinical Pearls for NEET-PG:** * **The Hallmark:** The most characteristic finding on a peripheral smear is **Hypersegmented Neutrophils** (defined as >5% of neutrophils having 5 lobes or a single neutrophil having ≥6 lobes) [1], [2]. * **MCV:** Typically >100 fL (often >110 fL) [2]. * **Pancytopenia:** Severe cases can present with low WBC and platelet counts due to ineffective hematopoiesis [3]. * **Biochemical markers:** Elevated Serum LDH and Indirect Bilirubin (due to intramedullary hemolysis). * **Bone Marrow:** Shows "sieve-like" or "checkered" chromatin pattern in erythroid precursors [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 654. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 593-594. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 594-595.

Question 989: Macrocytic anemia is seen in all of the following conditions EXCEPT:

A. Vitamin B12 deficiency
B. Hemolytic anemia
C. Post hemorrhagic anemia
D. Anemia of chronic disease (Correct Answer)

Explanation: **Explanation:** The classification of anemia is primarily based on the **Mean Corpuscular Volume (MCV)**. Macrocytic anemia is defined by an MCV >100 fL, whereas **Anemia of Chronic Disease (ACD)** is typically **normocytic normochromic**, though it can progress to **microcytic hypochromic** in long-standing cases [1]. **Why Option D is Correct:** In ACD, the primary pathology involves increased **Hepcidin** levels (induced by IL-6), which sequesters iron in macrophages and inhibits ferroportin [1], [2]. This results in low serum iron but normal-to-high ferritin. Because the defect involves iron utilization (similar to iron deficiency), the cells never become larger; they remain normal-sized or become smaller [1], [3]. **Why Other Options are Incorrect:** * **A. Vitamin B12 deficiency:** This is a classic cause of **megaloblastic macrocytic anemia**. Deficiency leads to impaired DNA synthesis, resulting in nuclear-cytoplasmic asynchrony where the nucleus matures slower than the cytoplasm, leading to large cells. * **B & C. Hemolytic and Post-hemorrhagic anemia:** These are causes of **non-megaloblastic macrocytosis**. In both conditions, the bone marrow responds to RBC loss by releasing **reticulocytes** (immature RBCs). Since reticulocytes are larger than mature RBCs, a high reticulocyte count falsely elevates the MCV. **High-Yield NEET-PG Pearls:** * **Megaloblastic Macrocytosis:** Characterized by hypersegmented neutrophils and macro-ovalocytes (e.g., B12/Folate deficiency, Drugs like Methotrexate). * **Non-Megaloblastic Macrocytosis:** No hypersegmented neutrophils; seen in Alcoholism, Liver disease, Hypothyroidism, and Reticulocytosis. * **ACD Hallmark:** Low Serum Iron + **High Ferritin** (distinguishes it from Iron Deficiency Anemia where ferritin is low) [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 660-662. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 658-659. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 590-591.

Question 990: Which among the following is the best laboratory test to estimate iron stores in the body?

A. Transferrin
B. Serum iron
C. Hemoglobin
D. Ferritin (Correct Answer)

Explanation: **Explanation:** **Serum Ferritin** is considered the most reliable and sensitive non-invasive laboratory test for estimating total body iron stores [1]. Ferritin is the primary intracellular storage protein for iron; while most of it resides in the liver, spleen, and bone marrow, the small amount secreted into the serum is directly proportional to the total body iron reserves [1]. In Iron Deficiency Anemia (IDA), a low serum ferritin level (<15-30 ng/mL) is highly specific and is the first biochemical marker to decline. **Why other options are incorrect:** * **Serum Iron:** This measures the amount of iron bound to transferrin in the circulation [1]. It fluctuates significantly based on recent dietary intake and diurnal variation, making it a poor indicator of long-term stores. * **Transferrin:** This is the transport protein for iron [1]. While its levels increase in IDA (measured as Total Iron Binding Capacity or TIBC), it reflects the body's *requirement* for iron rather than the actual *stores*. * **Hemoglobin:** This is a measure of the functional iron pool [1]. Hemoglobin levels only drop during the final stage of iron deficiency (Iron Deficiency Anemia), long after the storage pools have been depleted [3]. **High-Yield Clinical Pearls for NEET-PG:** * **The Gold Standard:** The absolute "Gold Standard" for assessing iron stores is a **Prussian Blue stain of a Bone Marrow aspirate**, but it is invasive and rarely performed for this purpose alone. * **The "Acute Phase" Caveat:** Ferritin is an **acute-phase reactant**. Its levels can be falsely elevated in the presence of inflammation, malignancy, or chronic liver disease, even if iron stores are low [2]. * **Sequence of depletion in IDA:** 1. Decreased Ferritin (Stores) → 2. Decreased Serum Iron/Increased TIBC (Transport) → 3. Decreased Hemoglobin (Functional). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 657-658. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 660-662. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 590-591.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free